SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 03, 2011 08:16 ET

Positive Regulatory Feedback Benefits Zalicus and Avanir Pharmaceuticals

The Paragon Report Provides Equity Research on Zalicus & Avanir Pharmaceuticals

NEW YORK, NY--(Marketwire - Nov 3, 2011) - The long journey through various stages of approval can make or break biotech companies that have spent countless hours and dollars on research and development. While many companies fail, the biotech industry has been garnering the attention of investors recently, as several firms have been able to successfully bring certain products to market both domestically and abroad. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Zalicus, Inc. (NASDAQ: ZLCS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:

Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Research and development expenses were $8.9 million in the quarter ended September 30, 2011 compared to $5.1 million in the quarter ended September 30, 2010. The $3.8 million increase was due primarily to an increase in expenses related to the clinical development of Synavive and preclinical development expenses related to our Ion channel product candidates, including Z160 and Z944.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Last month the company submitted an application to the European Medicines Agency (EMA) seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA).

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at